Why GLP-1s aren't lowering employers' costs
Summary
Host Weyland Wong and reporter Julie Wernow examine whether employer coverage for GLP-1 weight loss drugs saves money. Through the story of Nick Miller, whose state job covers his Ozempic, they explore the health benefits versus financial costs. Health economist Chris Whaley explains that while these drugs improve health, they currently increase employer spending rather than reducing it, challenging the assumption that better health automatically lowers insurance claims.
Topics discussed
Intro and Indicator Newsletter announcement
Nick's story: Ozempic, food noise, and employer coverage
Sponsors: Mattress Firm, HomeServe, and NPR membership
Nick's background and changing his view on medication
Employer strategy: Gatekeeping and health benefits
Economist Chris Whaley debunks cost-saving myths
Savings come from restrictions, not health outcomes
Conclusion, credits, and NPR promo segments
Listen ad-free on Castria